SCHEMBL3262187

SCHEMBL3262187

Fc1cc(Cl)cc2ncncc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
EGFR P00533 6/20 0.35
KDR P35968 3/20 0.34
FLT4 P35916 2/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
EPHB2 P29323 1/20 0.34
IDO1 P14902 1/20 0.33
NR4A2 P43354 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
MAP4K4 O95819 1/20 0.33
GRM1 Q13255 1/20 0.32
GRM4 Q14833 1/20 0.32
FGFR4 P22455 1/20 0.32
AURKA O14965 1/20 0.31
ERBB2 P04626 1/20 0.31
INSR P06213 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831645 0.80 CYP17A1 (0.35) EGFRKDRFGFR1FLT1IDO1
SCHEMBL13638715 0.80 CYP17A1 (0.35) EGFRKDRFGFR1FLT1IDO1
SCHEMBL3308499 0.77 EGFR (0.35) EGFRKDR
SCHEMBL31143775 0.77 EGFR (0.35) EGFRKDR
SCHEMBL25215782 0.73 EGFR (0.37) EGFRGRM1
SCHEMBL4036487 0.72 EGFR (0.47) MEN1KMT2AEGFRMAP4K4PDGFRB
SCHEMBL5334956 0.72 IDO1 (0.33) IDO1
SCHEMBL14678029 0.70 CSNK2A1 (0.38) KDRFGFR1NR4A2CSNK2A1MAP4K4
SCHEMBL16590447 0.70 POLB (0.36) MEN1KMT2ANR4A2CSNK2A2CSNK2B
SCHEMBL17838995 0.69 NR4A2 (0.62) MEN1KMT2AEGFRNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1720238-B Neurologically-active compounds PRANA BIOTECHNOLOGY LTD 2011-08-03 CN disclosed
EP-2210892-A2 Neurologically-active compounds Prana Biotechnology Limited (AU) 2010-07-28 EP disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed
EP-1558585-A4 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2008-07-02 EP disclosed
US-20060167000-A1 Neurologically-active compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2006-07-27 US disclosed
CN-1720238-A Neurologically-active compounds PRANA BIOTECHNOLOGY LTD (AU) 2006-01-11 CN disclosed
EP-1558585-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS Prana Biotechnology Ltd (AU) 2005-08-03 EP disclosed
WO-2004031161-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167000-A1 Neurologically-active compounds ACHE, PSEN1, PSEN2 MEN1 1487/4885KMT2A 2506/4885EGFR 4826/4885
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 MEN1 1991/4885KMT2A 2765/4885EGFR 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.